Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Donald

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Pediatric Infectious Disease Journal|January 6, 2006
Comparison of diagnostic criteria of tuberculous meningitis in human immunodeficiency virus-infected and uninfected childrenEsther M van der Weert, Nienke M Hartgers, H Simon Schaaf, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2014
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesSimbarashe P Zvada, Paolo Denti, Peter R Donald, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2022
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant TuberculosisLouvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2023
Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis"Louvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
Lancet (London, England)|May 22, 2010
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to actionBen J Marais, Mario C Raviglione, Peter R Donald, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Pediatric Infectious Disease Journal|January 6, 2006
Comparison of diagnostic criteria of tuberculous meningitis in human immunodeficiency virus-infected and uninfected childrenEsther M van der Weert, Nienke M Hartgers, H Simon Schaaf, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2014
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesSimbarashe P Zvada, Paolo Denti, Peter R Donald, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2022
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant TuberculosisLouvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2023
Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis"Louvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
Lancet (London, England)|May 22, 2010
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to actionBen J Marais, Mario C Raviglione, Peter R Donald, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Pageof 9